LOW-DOSE ENZALUTAMIDE AS SECOND-LINE HORMONE THERAPY IN CASTRATION-RESISTANT PROSTATE CANCER - TWO CASES
Dr. K. Diakité*, Z. Dahbi, A. Groulier, J. Perrin, S. Hny and V. Vinh-Hung
ABSTRACT
Enzalutamide at a recommended dosage of 160 mg / day is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) by improving overall survival in chemo-naive patients but also in those who progressed under docetaxel. It is also indicated in locally advanced disease. We report two cases of good tolerance and clinical remission with low-dose enzalutamide.
[Full Text Article] [Download Certificate]